Federico Pessina1, Pierina Navarria2, Luca Cozzi2, Stefano Tomatis2, Elena Clerici2, Anna Maria Ascolese2, Matteo Simonelli3, Matteo Perrino3, Marco Riva1, Marco Rossi1, Roberta Rudà4, Armando Santoro3, Lorenzo Bello1 & Marta Scorsetti2
1 Neurosurgery Oncology Department, Istituto Humanitas Cancer Center & Research Hospital, Rozzano, Italy
2 Radiotherapy & Radiosurgery Department, Istituto Humanitas Cancer Center & Research Hospital, Rozzano, Italy
3 Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
4 Neurooncological consultant Neurosurgery Oncology Department, Istituto Humanitas Cancer Center & Research Hospital, Rozzano, Italy
Aim: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions.
Methods: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria.
Results: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion.
Conclusion: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.
Read the complete pubblication at this link